摘要
目的 :探讨脑梗死亚型急性期血清神经元特异性烯醇酶 (NSE)和S - 10 0 β蛋白 (S - 10 0 β)变化的临床意义。方法 :5 9例急性脑梗死被分为全前循环梗死 (TACI)、部分前循环梗死 (PACI)、腔隙性梗死 (LACI)和后循环梗死 (POCI) ,以酶联免疫吸附试验 (ELISA)测定起病 6d内血清NSE和S - 10 0 β浓度的变化 ,同对照组比较。 结果 :TACI各时点的血清NSE浓度均高于对照组 (P <0 0 1) ,于第 3d达到高峰 ,PACI各时点的NSE浓度亦高于对照组 (P<0 0 5 ) ,于 1d达高峰。TACI的血清S - 10 0 β浓度与NSE同步升高 ;PACI的S - 10 0 β浓度则于 3h开始上升 ,1d达高峰 ,6h、1d、3d和 6d的浓度明显高于对照组 (P <0 0 5 )。LACI、POCI的血清NSE和S - 10 0 β无明显改变。 结论 :脑梗死亚型急性期 (含超早期 )血清NSE和S - 10 0 β浓度变化不同 。
AIM: To explore clinical significance of the serum changes of neuron-specific enolase (NSE)and S-100 β protein (S-100 β) during acute cerebral infarction. METHODS: 59 acute cerebral infarction patients were classified as total anterior circulation infarcts (TACI), partial anterior circulation infarcts (PACI), lacunar infarcts (LACI) and posterior circulation infarcts (POCI). Their serum NSE and S-100 β concentrations were determinated by enzyme linked immunosorbent assay (ELISA) during stroke onset 6 d, and compared with 32 controls. RESULTS: The every time point serum NSE concentration of TACI was higher than controls (P<0.01), and its highest value occured at 3 d after the onset. The every time point concentration of PACI was also higher than controls (P<0.05), its highest value occured at 1 d after the onset. The increment of serum S-100 β synchronized with serum NSE change in TACI. The S-100 β of PACI started to increase at 3 h after the onset, its highest value occured at 1 d after the onset, and concentration at 6 h, 1 d, 3 d and 6 d was markedly higher than controls (P<0.05). However, the every time point NSE and S-100 β concentrations of LACI and POCI increased unmarkedly compared with control group. CONCLUSIONS: The serum NSE and S-100 β changes in acute period (contains acute early period) of cerebral infarction subtypes might be different. These results might help to treat acute cerebral infarction according to the classification. [
出处
《中国病理生理杂志》
CAS
CSCD
北大核心
2004年第7期1290-1293,共4页
Chinese Journal of Pathophysiology
基金
广东省科委攻关基金资助项目 (No .99MO4 6 11G)
广东省中医药局基金资助项目 (No.10 30 5 2 )
